Literature DB >> 11799174

Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection.

Ayla Yenigün1, Belma Durupinar.   

Abstract

A genetically determined resistance or susceptibility to chronic hepatitis C virus (HCV) infection may make an important contribution to the course of liver disease and may be linked to the human major histocompatibility complex (MHC). The aim of this study was to investigate the HLA class II genotype profile in chronic hepatitis C and to determine the HLA-hepatitis C association. The experimental population was composed of 49 unrelated chronic HCV patients (31 females, 18 males; mean age, 54.4 +/- 1.7 years; range, 34 to 73 years). The control population consisted of 43 ethnically matched healthy donors. HLA-DR and -DQ alleles were studied for patients and controls by a PCR-sequence-specific-primer low-resolution method. Anti-HCV was investigated with enzyme-linked immunosorbent assay II, and HCV RNA was investigated with reverse transcriptase nested PCR. The HLA class II allele, DRB1*11, was found at reduced frequency in 49 patients with chronic hepatitis C (anti-HCV and HCV RNA positive) compared to that for controls (22.4 versus 51.0%; P < 0.01, odds ratio = 0.3, confidence interval = 0.1 to 0.7). No further HLA associations with chronic HCV infection were observed, and there was no correlation between the stage of disease and HLA. DRB1*11 was also found at reduced frequency in all HCV antibody-positive patients compared to controls (corrected P = not significant). DRB1*11 was associated with chronic HCV infection, and it is possible that HLA-DRB1*11 may have a protective feature in chronic HCV infection. In addition, DRB1*11 was associated with protection from HCV infection. These findings suggest that host HLA class II genotype is an important factor determining the outcome of infection with HCV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799174      PMCID: PMC135873          DOI: 10.1128/jvi.76.4.1787-1789.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids.

Authors:  C Tibbs; P Donaldson; J Underhill; L Thomson; K Manabe; R Williams
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

Review 2.  Is there a role for immune responses in the pathogenesis of hepatitis C?

Authors:  M U Mondelli
Journal:  J Hepatol       Date:  1996-08       Impact factor: 25.083

Review 3.  MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.

Authors:  R N Germain
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

4.  Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection.

Authors:  L Alric; M Fort; J Izopet; J P Vinel; J P Charlet; J Selves; J Puel; J P Pascal; M Duffaut; M Abbal
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

5.  Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C.

Authors:  C Zavaglia; M Martinetti; E Silini; R Bottelli; C Daielli; M Asti; A Airoldi; L Salvaneschi; M U Mondelli; G Ideo
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

6.  Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus.

Authors:  N Kuzushita; N Hayashi; T Moribe; K Katayama; T Kanto; S Nakatani; T Kaneshige; T Tatsumi; A Ito; K Mochizuki; Y Sasaki; A Kasahara; M Hori
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

7.  T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections.

Authors:  C Ferrari; A Valli; L Galati; A Penna; P Scaccaglia; T Giuberti; C Schianchi; G Missale; M G Marin; F Fiaccadori
Journal:  Hepatology       Date:  1994-02       Impact factor: 17.425

8.  T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia.

Authors:  M Lechmann; H G Ihlenfeldt; I Braunschweiger; G Giers; G Jung; B Matz; R Kaiser; T Sauerbruch; U Spengler
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

Review 9.  Immune responses in hepatitis C virus infection.

Authors:  U Spengler; M Lechmann; B Irrgang; F L Dumoulin; T Sauerbruch
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

10.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

View more
  14 in total

1.  HLA-DR11 and HLA-DR2 are negatively associated with autoantibody production in chronic hepatitis C.

Authors:  C-Y Hu; C-S Wu; C-S Lee; C-H Wu; H-F Tsai; P-J Chen; P-N Hsu
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

2.  Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis.

Authors:  Xin Hong; Rong-Bin Yu; Nan-Xiong Sun; Bin Wang; Yao-Chu Xu; Guan-Ling Wu
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles.

Authors:  Jouni Vesa; Antoine Chaillon; Gabriel A Wagner; Christy M Anderson; Douglas D Richman; Davey M Smith; Susan J Little
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

4.  Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes.

Authors:  Chuan-ging Wu; Anuradha Budhu; Sheng Chen; Xiaoling Zhou; Nicholas C Popescu; Kristoffer Valerie; Xin Wei Wang
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

Review 5.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

6.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Authors:  Evgeny Arons; Sharon Adams; David J Venzon; Ira Pastan; Robert J Kreitman
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

Review 7.  Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome.

Authors:  Viviana Romero; Jose Azocar; Joaquin Zúñiga; Olga P Clavijo; Daniel Terreros; Xiangjun Gu; Zaheed Husain; Raymond T Chung; Christopher Amos; Edmond J Yunis
Journal:  Mol Immunol       Date:  2008-03-04       Impact factor: 4.407

8.  HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites.

Authors:  Milton D Rossman; Bruce Thompson; Margaret Frederick; Mary Maliarik; Michael C Iannuzzi; Benjamin A Rybicki; Janardan P Pandey; Lee S Newman; Eleni Magira; Bojana Beznik-Cizman; Dimitri Monos
Journal:  Am J Hum Genet       Date:  2003-08-20       Impact factor: 11.025

Review 9.  A comparative review of HLA associations with hepatitis B and C viral infections across global populations.

Authors:  Rashmi Singh; Rashmi Kaul; Anil Kaul; Khalid Khan
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

10.  Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.

Authors:  Olfat Shaker; Heba Bassiony; Maissa El Raziky; Samer S El-Kamary; Gamal Esmat; Akmal M El-Ghor; Mona M Mohamed
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.